Clonal Hematopoiesis of Immunological Significance

ConditionsImmune System Diseases Autoimmune Diseases Inflammation Autoinflammatory Diseases Vexas Syndrome Hematopoiesis Clonal Clonal Hematopoiesis of Indeterminate Potential Hematologic Diseases Myelodysplastic-Myeloproliferative Diseases Leukemia Myelomonocytic Chronic Myelodysplastic Syndromes Myeloproliferative Disorders Lymphoproliferative Disorders Lymphoma Leukemia Monoclonal Gammopathy of Undetermined Significance

Trial statusNot yet recruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorAssistance Publique - Hôpitaux de Paris

About this trial

Ambispective, national, multicenter observational cohort study aimed at characterizing the satellite dysimmune manifestations of clonal hematopoiesis, including Vexas (Vacuoles, E1 enzyme, X-linked, Autoinflammatory and Somatic) syndrome.

Eligibility criteria

Qualifiers

Age >=18 years old;

Confirmed dysimmune manifestations: clinical or biological abnormality or systemic disease;

Presence or absence of myeloid or lymphoid blood disease according to World Health Organization (WHO) classification

Disqualifiers

Persons benefiting from special protection: adults under guardianship and curatorship;

People hospitalized without their consent and not protected by law; persons deprived of liberty;

Persons not affiliated to the social security system

Trial design

Treatments tested in this trial

observational cohort study

Treatment groups

5,000 Participants

are divided into 1 treatment group

Sponsors and collaborators

Assistance Publique - Hôpitaux de Paris

Lead sponsor

Sorbonne University

Collaborator

Institut National de la Santé Et de la Recherche Médicale, France

Collaborator

Club MINHEMON (MEDECINE INTERNE, HEMATO ET ONCO)

Collaborator

Source ClinicalTrials.gov